A Study of HMPL-295S1 in Patients With Advanced Malignant Solid Tumors

NCT04908046 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

47

Enrollment

INDUSTRY

Sponsor class

Conditions

Advanced Malignant Solid Tumors

Interventions

DRUG: HMPL-295S1 with dose escalation stage of 5mg up to 200mg, then expansion stage with recommended dose of therapeutic cycle of 28 days .

Sponsor

Hutchmed